Head to Head Survey: Neurometrix (NURO) versus CareFusion (CFN)

Neurometrix (NASDAQ: NURO) and CareFusion (NYSE:CFN) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, earnings, analyst recommendations, profitability, risk and dividends.

Earnings and Valuation

This table compares Neurometrix and CareFusion’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Neurometrix $17.09 million 0.55 -$14.91 million ($17.04) -0.08
CareFusion N/A N/A N/A $2.35 25.51

CareFusion has lower revenue, but higher earnings than Neurometrix. Neurometrix is trading at a lower price-to-earnings ratio than CareFusion, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

12.6% of Neurometrix shares are held by institutional investors. 4.4% of Neurometrix shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Neurometrix and CareFusion’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Neurometrix -75.24% -233.56% -136.11%
CareFusion 16.18% 12.80% 7.62%

Analyst Recommendations

This is a summary of current ratings and recommmendations for Neurometrix and CareFusion, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Neurometrix 0 0 1 0 3.00
CareFusion 0 0 0 0 N/A

Neurometrix presently has a consensus target price of $3.00, indicating a potential upside of 129.01%. Given Neurometrix’s higher probable upside, equities analysts clearly believe Neurometrix is more favorable than CareFusion.

About Neurometrix

NeuroMetrix, Inc. is a healthcare company combining bioelectrical and digital medicine to address chronic health conditions, including chronic pain, sleep disorders and diabetes. The Company is engaged in the sale of medical equipment, and consumables and accessories. It has two principal product lines: Wearable neuro-stimulation therapeutic devices and Point-of-care neuropathy diagnostic tests. Its products include ADVANCE NCS/EMG System (the ADVANCE System), Quell, SENSUS and DPNCheck. Quell is a wearable device for relief of chronic intractable pain, such as nerve pain due to diabetes and lower back problems. The SENSUS pain therapy device, the technological predecessor to Quell, is a prescription neuro-stimulation device based on transcutaneous electrical nerve stimulation (TENS) for relief of chronic, intractable pain. DPNCheck is a quantitative nerve conduction test. ADVANCE System is a platform for the performance of traditional nerve conduction studies.

About CareFusion

CareFusion Corporation is a global medical technology company. The Company operates in two business segments: Medical Systems and Procedural Solutions. The Company’s primary product brands include: Alaris intravenous (IV) infusion systems; Pyxis and Rowa automated medication dispensing and supply management systems; AVEA, Vela and LTV Series respiratory ventilators; ChloraPrep skin antiseptic products; MaxGuard, MaxPlus, MaxZero, SmartSite and Texium needle-free IV infusion valves, administration sets and accessories; V. Mueller and Snowden-Pencer open surgical and laparoscopic instrumentation; PleurX, Achieve and Temno interventional specialty products; AirLife disposable ventilator circuits and oxygen masks used for providing respiratory therapy; Vital Signs single-use consumables for respiratory care and anesthesiology; Jaeger and SensorMedics cardiopulmonary diagnostic equipment, and MedMined data mining surveillance software and analytics.

Receive News & Ratings for Neurometrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurometrix and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply